secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001493152-25-029107
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 3.03, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus raises $6M via convertible preferred; Lazar appointed Chairman and Co-CEO
--------------------------------------------------------------------------------

- David Lazar invests $6M for 300K Series AA and 700K Series AAA shares convertible into 111M common shares after stockholder approval.
- Lazar appointed Chairman and Co-CEO; board adds Avraham Ben-Tzvi; directors Martell and Karah resign.
- Special meeting by Mar 31, 2026 to approve conversion, authorized share increase, written consent, reverse split, and Lazar board nominees.
- Executive officers modify employment: reduce notice to 10 days, waive severance for stock/cash; CMO Waltzman resigns with $207K bonus.
- Issuance under Regulation S exemption; proceeds for operations, severance, working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315225029107/0001493152-25-029107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315225029107/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-029107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer